Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neuropeptide Y Y5 receptor antagonism causes faster extinction and attenuates reinstatement in cocaine-induced place preference

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effects of postnatal anoxia on striatal dopamine metabolism and prepulse inhibition in rats

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effect of erythropoietin on electroconvulsive stimulation induced cognitive impairment in rats

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Correction to: Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Glucagon-like peptide-1 (GLP-1) is a gut peptide that regulates food intake and glucose metabolism. GLP-1 is also produced and released in the brain, and GLP-1 receptors are expressed in brain regions important for alcohol and drug reward, and for the development of addiction. GLP-1 receptor agonists can decrease alcohol intake acutely in rodents. However, alcohol use disorder is a chronic condition that requires treatments to be effective in promoting abstinence from excessive alcohol consumption over time. Here, we assessed the effect of daily treatment with the GLP-1 receptor agonist Exendin-4 in an assay of relapse-like drinking in socially housed mice. Male C57BL/6NTac mice were allowed continuous access to alcohol without tastant in the home cage for 37days. Then, alcohol bottles were removed and Exendin-4 (1.5μg/kg/day) or saline was administered subcutaneously for 8days during alcohol deprivation. Treatment continued for 8 additional days after reintroducing access to alcohol. A high-precision automated fluid consumption system was used to monitor intake of alcohol and water, drinking kinetics, and locomotor activity. Exendin-4 prevented the deprivation-induced increase in alcohol intake observed in control mice, without significantly affecting total fluid intake, body weight, or locomotor activity. The reduced alcohol intake was caused by a protracted latency to the first drink of alcohol and a reduced number of drinking bouts, while bout size and duration were not affected. The effect was maintained undiminished throughout the treatment period. These findings support the possible use of GLP-1 receptor agonists in the treatment of alcohol use disorder.

Original languageEnglish
JournalPharmacology Biochemistry and Behavior
Volume160
Pages (from-to)14-20
Number of pages7
ISSN0091-3057
DOIs
Publication statusPublished - Sep 2017

    Research areas

  • Journal Article

ID: 52334753